Pedro Sudbrack-Oliveira1, Marina Zanichelli Barbosa1, Sigride Thome-Souza2, Lais Boralli Razza1, Jose Gallucci-Neto3, Leandro da Costa Lane Valiengo4, Andre Russowsky Brunoni5. 1. Service of Interdisciplinary Neuromodulation, Department and Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil; Laboratory of Neuroscience and National Institute of Biomarkers in Psychiatry, Department and Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil. 2. Video-EEG Unit, Department and Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil. 3. Neuropsychiatry Program, Department and Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil. 4. Service of Interdisciplinary Neuromodulation, Department and Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil; Laboratory of Neuroscience and National Institute of Biomarkers in Psychiatry, Department and Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil; Experimental Physiopathology Program, University of São Paulo Medical School, São Paulo, Brazil. 5. Service of Interdisciplinary Neuromodulation, Department and Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil; Laboratory of Neuroscience and National Institute of Biomarkers in Psychiatry, Department and Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil; Center for Clinical and Epidemiological Research & Interdisciplinary Center for Applied Neuromodulation, University Hospital, University of São Paulo, São Paulo, Brazil. Electronic address: brunoni@usp.br.
Abstract
PURPOSE: Current therapies for the management of epilepsy are still suboptimal for several patients due to inefficacy, major adverse events, and unavailability. Transcranial direct current stimulation (tDCS), an emergent non-invasive neuromodulation technique, has been tested in epilepsy samples over the past two decades to reduce either seizure frequency or electroencephalogram (EEG) epileptiform discharges. METHODS: A systematic review was performed in accordance with PRISMA guidelines (PROSPERO record CRD42020160292). A thorough electronic search was completed in MEDLINE, EMBASE, CENTRAL and Scopus databases for trials that applied tDCS interventions to children and adults with epilepsy of any cause, from inception to April 30, 2020. RESULTS: Twenty-seven studies fulfilled eligibility criteria, including nine sham-controlled and 18 uncontrolled trials or case reports/series. Samples consisted mainly of drug-resistant focal epilepsy patients that received cathodal tDCS stimulation targeted at the site with maximal EEG abnormalities. At follow-up, 84 % (21/25) of the included studies reported a reduction in seizure frequency and in 43 % (6/14) a decline in EEG epileptiform discharge rate was observed. No serious adverse events were reported. CONCLUSIONS: Cathodal tDCS is both a safe and probably effective technique for seizure control in patients with drug-resistant focal epilepsy. However, published trials are heterogeneous regarding samples and methodology. More and larger sham-controlled randomized trials are needed, preferably with mechanistic informed stimulation protocols, to further advance tDCS therapy in the management of epilepsy.
PURPOSE: Current therapies for the management of epilepsy are still suboptimal for several patients due to inefficacy, major adverse events, and unavailability. Transcranial direct current stimulation (tDCS), an emergent non-invasive neuromodulation technique, has been tested in epilepsy samples over the past two decades to reduce either seizure frequency or electroencephalogram (EEG) epileptiform discharges. METHODS: A systematic review was performed in accordance with PRISMA guidelines (PROSPERO record CRD42020160292). A thorough electronic search was completed in MEDLINE, EMBASE, CENTRAL and Scopus databases for trials that applied tDCS interventions to children and adults with epilepsy of any cause, from inception to April 30, 2020. RESULTS: Twenty-seven studies fulfilled eligibility criteria, including nine sham-controlled and 18 uncontrolled trials or case reports/series. Samples consisted mainly of drug-resistant focal epilepsypatients that received cathodal tDCS stimulation targeted at the site with maximal EEG abnormalities. At follow-up, 84 % (21/25) of the included studies reported a reduction in seizure frequency and in 43 % (6/14) a decline in EEG epileptiform discharge rate was observed. No serious adverse events were reported. CONCLUSIONS: Cathodal tDCS is both a safe and probably effective technique for seizure control in patients with drug-resistant focal epilepsy. However, published trials are heterogeneous regarding samples and methodology. More and larger sham-controlled randomized trials are needed, preferably with mechanistic informed stimulation protocols, to further advance tDCS therapy in the management of epilepsy.
Authors: Ángel Canal-Alonso; Roberto Casado-Vara; Orlando Castellano; Jorge Herrera-Santos; Jaime Gonçalves; Sergio Màrquez-Sànchez; Jesús María Gonçalves; Juan Manuel Corchado Journal: Philos Trans A Math Phys Eng Sci Date: 2022-06-06 Impact factor: 4.019
Authors: Giordano D'Urso; Elena Toscano; Veronica Sanges; Anne Sauvaget; Christine E Sheffer; Maria Pia Riccio; Roberta Ferrucci; Felice Iasevoli; Alberto Priori; Carmela Bravaccio; Andrea de Bartolomeis Journal: J Clin Med Date: 2021-12-28 Impact factor: 4.241
Authors: Jose Antonio Camacho-Conde; Maria Del Rosario Gonzalez-Bermudez; Marta Carretero-Rey; Zafar U Khan Journal: CNS Neurosci Ther Date: 2021-12-03 Impact factor: 5.243
Authors: David Haslacher; Nikolina Novkovic; Maria Buthut; Andreas Heinz; Surjo R Soekadar Journal: Front Psychiatry Date: 2022-03-24 Impact factor: 4.157